01 / The thesis

Discovery is accelerating.
Translation is still the bottleneck.

Promising programs stall when biology, modality, rights, CMC, clinical strategy and leadership are treated as separate problems.

SCROLL

The category error

The market often writes off a target when only one therapeutic configuration failed.

A failed experiment can close a chapter. It should not silently close the entire biology.

OBSERVEREASSESSPROVE

The re-underwriting moment

01 / 03

The target failed.

Markets compress a specific clinical result into a broad category judgment. The shorthand travels faster than the evidence.

A verdict is not a mechanism.

The opportunity

Not rescuing failed science.
Finding where the verdict is broader than the evidence.

  1. 01Re-underwrite the original decision.
  2. 02Design the next decisive proof.
  3. 03Secure differentiated rights before the story gets crowded.
See how the engine moves